Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Delay to the TIL therapy announced by Iovance last night
https://www.globenewswire.com/news-release/2020/10/05/2103814/0/en/Iovance-Biotherapeutics-Provides-Update-for-Lifileucel-in-Metastatic-Melanoma.html
They're taking a 20% hit pre-market, think it's having a knock on effect on Clin
They don't call you CrystalBall for nothing.
This is too big of a fall to be based on nothing though.
Such is life in the Alternative Investment Market. It’s volatile. Sharp unexplained fluctuations happen.
as fast as this hits 700, it then drops 30p below, for a share of this "value" these large fluctuations tell you all you need to know, the market does not value this as highly as the company believes it should be, it's bouncing off what i would say is it's upper value right now, In the last week alone the change has been circa 70p (in the right direction i might add) but next week could be 70p in the other direction.
Nice to see this above 700p
In italy you can mix and match nhs and private. When my wife was dying of melanoma we had some scans private. Cost was €500 same in UK about £2500
Spinnaker, thanks for adding the wiki extract.
The important point is that there will be paperwork For the doctor to get someone (NHS, insurer or individual) to pay. Hence volumes are likely to be lower until fully licensed. However CLIN has an established system cliniport to support doctors with the supply of the drugs.
The differentiation and promotion of the SNG solution will be key to get doctors to persevere with the bureaucracy.
Jatw
Thank you for your response to my post. I note what you say. The ' Wiki' extract below seems to imply that the NHS will pay if the treating doctor agrees with the patient that it is an appropriate drug and/or there is no alternative treatment. I have heard previously that the NHS and private medicine cannot be mixed and therefore whilst under NHS care a patient or their insurers cannot pay for/ provide a non NHS treatment. I would also expect that the NHS would seek to prevent an ill or infectious patient discharging themselves. Also there were not any private hospitals taking Covid patients in March or since.
If this is the case then the patient won't be able to have and pay for SNG001 if the NHS won't fund the supply. Am I correct or perhaps you or another knowledgeable poster can enlighten me as to the correct position?
I attach an extract from the Wiki entry which states the NHS would pay but this may be incorrect or outdated.
Many thanks
Spinnaker
'Europe
In Europe, the European Medicines Agency issued guidelines that members may follow. Each country has its own regulations, and they vary. In the UK, for example, the program is called "early access to medicine scheme" or EAMS and was established in 2014. If a company that wants to provide a drug under EAMS, it must submit its Phase I data to the Medicines and Healthcare products Regulatory Agency and apply for what is called a "promising innovative medicine" (PIM) designation. If that designation is approved, the data is reviewed, if that review is positive, the National Health Service is obligated to pay for people who fit the criteria to have access to the drug. As of 2016, governments also paid for early access to drugs in Austria, Germany, Greece, and Spain.[1]
Companies sometimes make use of expanded programs in Europe even after they receive EMA approval to market a drug, because drugs also must go through regulatory processes in each member state, and in some countries this process can take nearly a year; companies can start making sales earlier under these programs.[1]'
Spinnaker,
Clinigen should have expertise to help SNG. They may be helping out plan the Phase III trials to get regulatory approvals, the MAP should help sell the product to named patients in hospital....likely to be privately paid for rather than state supported so volumes will be lower than when this treatment is fully licensed and state funded....at which point Clin also has distribution capabilities.
CLIN should help SNG accelerate their product through regulatory approval and distribution...If the product is successful .the deal is positive for both sides.....but as in all things the distributors may make more risk adjusted profit....
Hello everyone.
I am not a holder here but have just come to have a look at your board since I am a shareholder in Synairgen. There is a fair bit of frustration amongst SNG PIs that the potentially game changing nebulised interferon drug, SNG001, repurposed for Covid-19 treatment has had a fantastic result for the hospital element of the Phase II clinical trial but the home treatment element of the trial has not yet been filled even though access is available nationally. Also there has been no news about a Phase 3 trial here or abroad.
The SP has dropped further today following the RNS concerning MAP and Clinigen tie up but it is good to see CLIN SP has reacted positively. I have little knowledge about MAP but it appears CLIN is experienced with supporting drugs in this field and this should be helpful in getting SNG to patients who could benefit greatly in the short term and ensuring all hospitals and doctors here and across Europe have the knowledge of the likely benefits to patients and a chance of accessing this currently singular treatment available for Covid patients prior to intubation.
I am hopeful that CLIN can help SNG save numerous lives this winter. Good Luck to all patients and shareholders.
Spinnaker
Biggest benefit is keeping CLIN in the news with a positive story.
A MAP is a common thing for CLIN....and aside from their own portfolio is the greatest good the company does by making available treatments early or in unlicensed countries.
No I think the question is willl it be big enough or unexpected to make a difference here ...
The drug in question had hugely promising phase 2 results announced late July which attracted international publicity and a mention from Matt Han**** in the House of Commons. The SP multiplied x4 although there has been a gradual decline since then on new news. It is a small Company consisting of around 16 staff members. Great science and an impressive CEO but needs help from the big boys if they are going to get their product on the shelves
Synairgen. Check their message board and that will tell you all you need to know.
SNG ?
Flat across the week having gone down and recovered.
Atleast the rot was stopped this week.....
Proleukin trial impacted by pandemic. Forecast sluggish growth 1H 2021. In the absence of a bid for the Company then yeh, unwise to anticipate any significant increase in SP in the short term but hey, AIM is a volatile beast
I’m comfortable holding and looking forward to cash generating Proleukin news in 2021 and the promised accelerated growth in 2022.
Solid results, but not much to excite... nothing new really. I think I'm going to sit on the side & watch for the next 12-18 months, but i can't see it breaking out of the 5-7 range without something like a takeover bid... funny how the market values a business isn't it? Next post a result of -94% profit and the share price rises 4%... this lot post +20% profit, and the share price droops like last weeks celery! I think this one will start to agitate in the 12-18 month timescale... Happy to be proved wrong, and i'll hold for now & topup on any weakness
Seems to me that Proleukin renewal is key to any SP growth.....per their presentation this would result in exceeding the top end of 10% EBITDA growth.
Roll on news from Iovance.
agreed, the dividend is ridiculously tiny, and almost pointless, waste not reducing the debt this time around.
especially as they have managed to push a profit through a good chunk of the covid lockdown, no doubt as they said thanks due to their workers (i have no doubt the execs all hid at home!)
but again, company making good progress while many others are folding, and the share price.... yeah no where near where they think they are worth, that speaks volumes and tells you where the market rates this at
14% increase in full year dividend. Nice but I would have preferred to have seen a reduction in debt instead.
Organic growth forecast to continue then, and and any positive Proleukin news will really fire the burners
In at 650, out at 661. Enough to buy a decent lunch. Warren Buffet or what!
Nd
In at 650, out at 661. Enough to buy a decent lunch. Warren Buffet or what!
Nd
EPS up 20%
Net debt to increase 1 H 2021
Organic growth forecast at lower end of 5% - 10% range 2021 with accelerated growth 2022. Well, I reckon 5% growth seen against the backdrop of Covid would be on the wish list of most businneses
One of the few companies to get such good results.